Exasol Announces Expanded Capabilities of Its Analytics SaaS Database, Including ETL Integration
3.5.2022 11:00:00 EEST | Business Wire | Press release
Exasol, the market leading high-performance analytics database, has announced that from today, Exasol SaaS – the scalable, consumption-based SaaS database based on Amazon Web Services (AWS) – now natively interfaces with Keboola, a cloud-based Data Stack as a Service platform. Keboola provides the first complete solution for data engineers, data analysts, and analytics engineers to deliver on the full spectrum of data demands – from data ingestion to automation. Users will benefit from a built-in function that connects them directly to Keboola from Exasol’s SaaS interface. The Keboola low-code platform provides more than 250 integrations for building ETL/ELT and other pipelines, automation, one-click workflows with integrated business case templates, as well as enterprise grade data governance over the entire stack. It’s a combination that provides improved data accuracy and reduces the time to value.
Commenting on the news, Milan Veverka, VP of Alliances at Keboola said: “We believe that by surrounding ourselves with amazing people, we can achieve anything. That's why we focus on building partnerships that matter. Partnerships with companies that have a similar mindset as we do - empowering everyone to make data-driven decisions. Keboola and Exasol provide great solutions together. We built a simple to use, cost-effective and easy to maintain Data Stack as a Service while Exasol provides its fast in-memory database that helps customers to get to their solution. Together we will make both the implementation and the queries themselves much faster for shared customers.”
In addition to the new collaboration with Keboola, Exasol has introduced a series of new product capabilities that expand on its fully managed, SaaS offering. The new product capabilities will further enhance a customer’s ability to access data-led insights quickly, without needing to manage hardware infrastructures. These innovations include:
- Enhanced AI/ML capabilities: Customers can now solve complex analytics challenges with ease, such as predictive analytics, by bringing in AI/ML algorithms directly to the data. Operationalizing ML models will also bring maximum performance within the database to its users.
- Data virtualization support: Analysts will be able to access objects from external sources without the need for migrating data. This support will also eliminate the need for the costly management of duplicate data. It will allow users to more easily access their data – whether it’s stored locally or in the cloud – and set-up or create a logical data warehouse.
- Amazon SageMaker extension: Exasol SaaS now supports a SageMaker Extension, enabling users to develop end-to-end machine learning projects on data stored in Exasol using the Amazon SageMaker Autopilot service. Doing so mean users can turn data into actionable insights in a matter of minutes.
“When it comes to an organization’s data strategy, data leaders are looking for the confidence to modernize with market-proven, enterprise capabilities that offer flexible migration paths – often to the cloud – at a pace and time that fits with budget and resource constraints,” says Donald Kaye, Chief Commercial Officer at Exasol. The impact of this decision can be profound: affecting costs, the pace of innovation, production releases, marketing penetration and security, to name just a few. “To address the complex challenges organizations face when looking to garner actionable insight from their data, we announced, in February, the strengthening of our hybrid cloud proposition by making our high-performance analytics database available via Exasol SaaS.”
Exasol SaaS is available in two versions. The Exasol SaaS Standard Edition delivers industry leading performance on-demand for organizations with smaller data volumes who don’t require advanced analytics and data integration features or extended support. The Exasol SaaS Enterprise Edition is designed for organizations that require multi-departmental analytics environments, need to perform ML or AI in the database, or have complex requirements in terms of data integration and data virtualization.
Both versions of Exasol SaaS are available here.
About Exasol
Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.
Exasol – the leading Performance Analytics Database powering insights from the world’s data.
Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005032/en/
Contact information
Isabella Alder, EMEA PR Manager at Exasol
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
